Clinical Outcomes of Switching From Warfarin to Apixaban or Rivaroxaban in Patients With Atrial Fibrillation: A Nationwide Multidatabase Study
- 27 August 2025
- journal article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (9) , e011890
Abstract
BACKGROUND: The benefits of switching from warfarin to direct oral anticoagulants in atrial fibrillation remain unclear. METHODS: This retrospective study used the Medicare fee-for-service (2013–2020) and Optum Deidentified Clinformatics Data Mart databases (2013–2023). Among patients with atrial fibrillation who received warfarin for at least 180 days, we created 2 cohorts: (1) patients switching to apixaban versus continuing warfarin (the apixaban cohort) and (2) patients switching to rivaroxaban versus continuing warfarin (the rivaroxaban cohort). The index date was the switch date for switchers and a matched date based on warfarin duration for warfarin continuers. After 1:1 propensity score matching, we estimated the rate ratios (RR) for a composite of ischemic stroke, major bleeding, and death in each database and pooled the results using meta-analysis. Subgroup analyses by claims-based frailty and by follow-up time (first 60 days versus beyond 60 days) were performed. RESULTS: In the apixaban cohort (n=164 480; mean age, 80.5 years; 55.5% female; median follow-up, 354 days), switching to apixaban was associated with a lower rate of composite outcome (97.1 versus 104.9 per 1000 person-years; rate ratio, 0.92 [95% CI, 0.89–0.95]) compared with continuing warfarin. In the rivaroxaban cohort (n=96 030, mean age 79.7 years, 54.8% female, median follow-up 365 days), switching to rivaroxaban was associated with an increased rate of composite outcome (105.8 versus 99.3 per 1000 person-years; rate ratio, 1.08 [95% CI, 1.04–1.13]). No heterogeneity by frailty levels was observed. However, switching was associated with an initial risk increase within the first 60 days, followed by risk attenuation beyond 60 days, for both apixaban and rivaroxaban. CONCLUSIONS: In patients with atrial fibrillation on warfarin therapy, switching to apixaban may reduce the risk of ischemic stroke, major bleeding, and death, whereas switching to rivaroxaban may increase the risk. For both apixaban and rivaroxaban, switching may temporarily increase risk during the first 60 days.Keywords
This publication has 49 references indexed in Scilit:
- What Does the Proposed Causal Inference Framework for Observational Studies Mean for JAMA and the JAMA Network Journals?JAMA, 2024
- Causal Inference About the Effects of Interventions From Observational Studies in Medical JournalsJAMA, 2024
- Frailty, Home Time, and Health Care Costs in Older Adults With Atrial Fibrillation Receiving Oral AnticoagulantsJAMA Network Open, 2023
- Emulation of Randomized Clinical Trials With Nonrandomized Database AnalysesJAMA, 2023
- Comparative Effectiveness and Safety of Oral Anticoagulants by Dementia Status in Older Patients With Atrial FibrillationJAMA Network Open, 2023
- Target Trial EmulationJAMA, 2022
- Trends in Use of Oral Anticoagulants in Older Adults With Newly Diagnosed Atrial Fibrillation, 2010-2020JAMA Network Open, 2022
- Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial FibrillationJAMA, 2021
- An automated database case definition for serious bleeding related to oral anticoagulant usePharmacoepidemiology and Drug Safety, 2011
- Validation of ICD‐9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health dataPharmacoepidemiology and Drug Safety, 2007